文献速递毛发、甲与色素性疾病

5α-还原酶抑制剂治疗前额纤维化性脱发:基于证据的治疗更新

5-alpha-reductase inhibitor treatment for frontal fibrosing alopecia: an evidence-based treatment update.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-03-30

该综述检索2005至2017年关于5α-还原酶抑制剂(5ARI)治疗前额纤维化性脱发(FFA)的文献,按美国内科医师学会结局研究分级系统评估。两项中等证据等级研究显示5ARI多作为难治性疾病的辅助治疗获阳性结果,但安全性证据有限。作者认为设计良好的随机双盲对照研究将强化5ARI在FFA治疗中的地位。

要点

  • 两项中等证据等级研究描述了5ARI治疗FFA的疗效,多作为难治性疾病的辅助治疗获阳性结果。
  • 一项2级和三项较低级别研究(一项3级、两项4级)报告了轻度至中度毛发再生。
  • 大多数分析的研究中关于该药物安全性的证据有限。

核心结论

  • 本综述表明,接受5ARI治疗的FFA患者在部分病例中可实现疾病稳定或进展速度减慢。
  • 作者认为,设计良好的随机双盲对照研究将强化5ARI作为FFA治疗手段一部分的地位。

研究设计与样本

  • 对2005年至2017年间发表的关于5ARI治疗FFA的文章进行综述、分析,并按美国内科医师学会结局研究分级系统进行分级。

主要发现

  • 有两项中等证据等级研究描述了5ARI治疗FFA的疗效。
  • 5ARI常作为难治性疾病的辅助治疗,并取得阳性结果。
  • 一项2级和三项较低级别研究(一项3级和两项4级)报告了轻度至中度毛发再生。
  • 大多数分析的研究中关于该药物安全性的证据有限。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 数据库研究可能无法完全校正混杂因素,且受方法学和数据收集变异的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment for frontal fibrosing alopecia (FFA) is challenging, and its treatment regimen often mirrors other lymphocytic-predominant cicatricial alopecia. 5-alpha-reductase inhibitor (5ARI) has been reported with some treatment success in severe cases of FFA. OBJECTIVE: To carry out evidence-based analysis of articles published on treatment efficacy and safety of 5-alpha-reductase inhibitor for the treatment of FFA. METHODS: Articles published on the use of 5ARI to treat FFA between 2005 and 2017 were reviewed, analysed and graded according to the American College of Physicians outcome study grading system. RESULTS: There were two studies with moderate level of evidence that described the efficacy of 5ARI for the treatment of FFA. 5ARI was commonly used as adjunctive therapy with positive results in recalcitrant disease. Mild to moderate hair regrowth was reported in one grade 2 and three lower grade (one grade 3 and two grade 4) studies. There is limited evidence on the safety aspects of this medication in most studies that were analysed. LIMITATIONS: Database studies might not fully account for confounders and are subjected to variations in methodology and data collection. CONCLUSION: This review demonstrated that FFA patients treated with 5ARI could achieve either disease stability or reduction in the rate of progression in selected cases. A well-designed randomized, double-blind, controlled study would strengthen the role of 5ARI as part of treatment armamentarium for FFA.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Murad A, Bergfeld W. 5-alpha-reductase inhibitor treatment for frontal fibrosing alopecia: an evidence-based treatment update. J Eur Acad Dermatol Venereol. 2018. PMID: 29524253. doi:10.1111/jdv.14930

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。